Since 1990, helping busy clinicians master the science and art of caring for people with HIV disease.

Latest News

July 18, 2011

IAS 2011: Final Data on ARIES Study Released


Final Data on ARIES Study Released

Dr. Kathleen Squires, a researcher at the Thomas Jefferson University Hospital, presented long awaited final (144 week) results from the ARIES study at the IAS conference in Rome. ARIES is a study investigating the outcomes of ARV naive HIV-1 infected persons who were started on a regimen of ABC/3TC + atazanavir/ritonovair. At week 36 the participants were randomized to continue this regimen (continuation arm) or the alternate, ABC/3TC plus unboosted atazanavir 400mg (simplication arm). This was the first study to use the HLA*B5701 screening test for abacavir hypersensitivity for all participants. Patients at week 84 without virologic failure were followed through the extension phase to week 144. 369/379 subjects entered the extension phase and these were the results reported. Similar efficacy was noted for both regimens with no significant differences noted for mean CD4 counts or HIV-1 RNA <50, TLOVR. Grade 2-4 adverse effects were higher in the atazanavir/ritonavir arm, predominantly due to an increase in hyperbilirubinemia (14% vs 6%). Total cholesterol, triglycerdies and cholesterol/HDL ratio demonstrated more favourable profiles for subjects enrolled in the simplification arm. Simplication to a ritonoavir-sparing regimen may be appropriate for some patients, for example, those with cardiovascular disease who may benefit from a more favorable lipid profile or for those in whom hyperbilirubinemia is a concern.

Reference: Squires K, Young B, DeJesus E, et al. Similar efficacy and tolerability of atazanavir (ATV) compared to ATV/ritonavir (RTV), each in combination with abacavir/lamivudine (ABC/3TC), after initial suppression with ABC/3TC + ATV/RTV in HIV-1 infected patients: final (144 weeks) results of the open label, multicenter, non-inferiority ARIES study [Abstract]. Presented July 18, 2011 at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy. Poster Presentation #MOPE215.


Source: Reporting for PRN News from Rome, Italy: Anita Radix, MD